Overview
Short Course: October 30 | Virtual
Short Course: November 2 | Virtual
Meeting: November 7-8 | In-Person
The DIA Canada Annual Meeting will deliver a comprehensive overview of the current pharmaceutical, medical device, and/or diagnostic landscapes in Canada, while sharing insights into Canada’s broader role in global healthcare product development and is separated into three tracks: Regulatory, Clinical and Pharmacovigilance. This meeting will connect attendees with leaders and experts in academia and those involved in the regulatory, clinical, and pharmacovigilance functional areas in the pharmaceutical and medical device industry to explore best practices, lessons learned, and problem-solving strategies effecting stakeholders in Canada.
Need approval in order to attend? Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.
Participant Testimonials
Very insightful conference. Time well invested.” - Thierry Page, Executive VP, COO, Starpax Biopharma Inc.
“The best conference for Canadian content of 2022.” - Patricia Smith, Director, Regulatory Affairs, QA and PV, Otsuka Canada Pharmaceutical Inc.
Featured
Short Course or Primer
-
Nov 02, 2023
Global Advertising and Promotion – Considerations for Compliance and Success
Learn more -
Oct 30, 2023
Tools and Methods to Evaluate the Effectiveness of Risk Minimization Measures
Learn more
Who should attend?
-
Meeting Designed For
Join professionals interested in a comprehensive overview of the current biopharma pharmaceutical, medical device, and/or diagnostics landscape in Canada:
- Pharmacovigilance and Drug Safety
- Risk Management
- Clinical Research, Management, and Operations
- Regulatory Affairs and Operations
- Medical Affairs and Scientific Communication
- Quality Assurance
- Life Sciences R&D
- Project Management
- Real-World Data and Real-World Evidence
- Data Management
-
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Contextualize the Agile Licensing for Drugs initiative within Health Canada’s (HC’s) Regulatory Innovation Agenda
- Identify key themes and feedback heard during HC’s consultation period, including the use of terms and conditions, risk management plans, and rolling reviews
- Describe current efforts to increase equitable drug development and regulatory systems
- Identify regulatory frameworks and policies to support advanced therapeutic products and devices in Canada
- Gain insights on international collaboration initiatives in place to support timely access to medicines in Canada
- Define specific attributes of HC’s regulatory requirements on HC’s Nitrosamines Impurities Guidance and utilization of international collaboration to inform regulatory requirements and decisions
- Gain insights on how to optimize clinical trials operationally in Canada
- Identify the most common good pharmacovigilance practices (GVP) inspection findings
- Gain insights on considerations around global collaboration and reliance regarding digital advancements in regulatory data transformation
- Identify key elements of effective clinical supply chain
- Define transparency requirements for sponsors and expectations from regulators
left-video
Program Committee
-
Maria Anillo • Regulatory Affairs Project Manager
AstraZeneca Canada Inc., Canada -
Marcia Bailey, BSN, MHS, RN • Safety Evaluation and Risk Management Scientific Director
GSK, Canada -
Vatche Bartekian, MSc • President
Vantage BioTrials, Canada -
Mandy Collier • Director, Health Products and Food Branch
Health Canada, Canada -
Melanie Cote, MS • Senior Manager, Regulatory Affairs
Otsuka , Canada -
My Dang • Senior Manager, Regulatory Affairs and Quality Assurance
Knight Therapeutics Inc. , Canada -
Tharany Ganesh, MSc • Director, Regulatory Affairs & Quality Assurance
AstraZeneca Canada Inc., Canada -
Lorella Garofalo, PhD • Head of Regulatory Sciences
Pfizer Canada, Canada -
Marie-France Goyer, MSc • Director, Clinical Operations
Abcellera, Canada -
Brenda Gryfe, MSc • Director, Regulatory Affairs
TPIreg/ Innomar Strategies, Canada -
Oxana Iliach, PhD • Senior Director Regulatory Strategy
Certara, Canada -
Agnes Jankowicz, MS • Vice President, Pharmacovigilance
Veristat, Canada -
Nadiya Jirova, MSc • Manager, Bureau of Biologics, Radiopharmaceuticals and Self-Care Products
Health Canada, Canada -
Yatika Kohli, PhD, MBA • Chief Regulatory and Strategy Officer
NoNO Inc, Canada -
Nadia Mian, MS • Pharmacovigilance Manager
Ipsen Biopharmaceuticals Canada Inc, Canada -
Myriam Salem, MSc • Senior Corporate Regulatory and Enforcement Advisor
Health Canada, Canada -
Marcia Sam • Regulatory Affairs Strategy and Policy Manager
Hoffmann-La Roche Canada Limited, Canada -
Vanessa Zapata • Associate Director, Regional Pharmacovigilance Officer
Merck Canada Inc., Canada -
Zohra Douida, MPharm, MS, MSc • Head, Regulatory Affairs Canada
Indivior Canada Inc., Canada -
Amber McLeod, PhD • Lead, Regulatory Affairs
Abbvie Corporation, Canada -
Representative Invited • DIA, United States
Contact us
Registration Questions?
Additional Information
Discover DIA’s Live In-Person EventsDownload and fill out our Justification Letter
Canada Annual Meeting Call for Abstracts
